Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (16885)	3/9/1998 11:14:00 AM
From: Flagrante Delictu	Respond to of 32384

Henry, Re: Patent 5,723,329. The abstract says, "The receptors of the present invention differ significantly from known retinoic acid receptors, in protein primary sequence and in responsiveness to exposure to various retinoids". The last sentence says, " The invention also provides nucleic acid probes for identifying DNAs which encode additional retinoid receptors of the same class as the novel novel receptors disclosed herein". I am confused by the classification of the newly found receptors as significantly different from known retinoic acid receptors, and the mention in the closing sentence of "additional retinoid receptors of the same class as the novel receptors disclosed herein". Are we to conclude that although they are significantly different they are still retinoid receptors and not a different class of receptors? Bernie